



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering : 200,000,000 Shares (subject to reallocation and the Over-allotment Option)
Number of Hong Kong Offer Shares : 20,000,000 Shares (subject to reallocation)
Number of International Offer Shares : 180,000,000 Shares (subject to reallocation and the Over-allotment Option)
Maximum Offer Price : HK\$3.00 per Offer Share, plus brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal value : HK\$0.01 per Share
Stock code : 1652

全球發售

全球發售的發售股份數目 : 200,000,000 股股份 (可予重新分配及視乎超額配股權行使情況而定)
香港發售股份數目 : 20,000,000 股股份 (可予重新分配)
國際發售股份數目 : 180,000,000 股股份 (可予重新分配及視乎超額配股權行使情況而定)
最高發售價 : 每股發售股份 3.00 港元，另加 1% 經紀佣金、0.0027% 證監會交易徵費及 0.005% 聯交所交易費 (須於申請時以港元繳足，多繳股款可予退還)
面值 : 每股股份 0.01 港元
股份代號 : 1652

Application Form 申請表格

Please read carefully the prospectus of Fusen Pharmaceutical Company Limited (the "Company") dated Thursday, June 28, 2018 (the "Prospectus") (in particular, the section "How to Apply for Hong Kong Offer Shares" in the Prospectus) and the guide on the back of this Application Form before completing this Application Form. Terms defined in the Prospectus together with any supplement thereto have the same meanings when used in this Application Form unless defined herein.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and Hong Kong Securities Clearing Company Limited ("HKSCC") take no responsibility for the contents of this Application Form, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of this Application Form.

A copy of this Application Form, together with a copy of each of the WHITE and YELLOW Application Forms, the Prospectus and the other documents specified in the section headed "Documents Delivered to the Registrar of Companies in Hong Kong and Available for Inspection" in Appendix V to the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The Securities and Futures Commission (the "SFC") and the Registrar of Companies in Hong Kong take no responsibility as to the contents of any of these documents.

Your attention is drawn to the paragraph headed "Personal Data" in the section "How to Apply for Hong Kong Offer Shares" in the Prospectus which sets out the policies and practices of the Company and the Hong Kong Share Registrar in relation to personal data and compliance with the Personal Data (Privacy) Ordinance.

Nothing in this Application Form or the Prospectus constitutes an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Hong Kong Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This Application Form and the Prospectus are not for distribution, directly or indirectly, in or into the United States, nor is this application an offer of Shares for sale in the United States. The Offer Shares have not been and will not be registered under the U.S. Securities Act or any state securities law in the United States and may not be offered, sold, pledged or transferred within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. The Offer Shares may only be offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and the applicable laws of each jurisdiction where those offers and sales occur. No public offering of the Offer Shares will be made in the United States.

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction. This Application Form and the Prospectus are addressed to you personally. Any forwarding or distribution or reproduction of this Application Form or the Prospectus in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the U.S. Securities Act or the applicable laws of other jurisdictions.

To: Fusen Pharmaceutical Company Limited
Sole Sponsor
Joint Global Coordinators
Joint Bookrunners
Joint Lead Managers
Hong Kong Underwriters

在填寫本申請表格前，請仔細閱讀福森藥業有限公司（「本公司」）於2018年6月28日（星期四）刊發的招股章程（「招股章程」）（尤其是招股章程「如何申請香港發售股份」一節）及刊載於本申請表格背面的指引。除另有界定，本申請表格所使用詞彙與招股章程連同其任何補充文件所界定者具相同涵義。

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司（「香港結算」）對本申請表格內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不會就因本申請表格全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。

本申請表格連同白色及黃色申請表格、招股章程及招股章程附錄五「送呈香港公司註冊處處長及備查文件」一節所指明的其他文件，已遵照香港法例第32章公司（清盤及雜項條文）條例第342C條的規定送呈香港公司註冊處處長登記。證券及期貨事務監察委員會（「證監會」）及香港公司註冊處處長對這些文件的內容概不負責。

敬請閣下留意招股章程「如何申請香港發售股份」一節內的「個人資料」一段，當中載有本公司及本公司的香港證券登記處有關個人資料及遵守《個人資料（私隱）條例》的政策及慣例。

本申請表格或招股章程所載者概不構成出售要約或要約購買的游說，而在任何作出有關要約、游說或出售即屬違法的司法權區內，概不得出售任何香港發售股份。本申請表格及招股章程不得在美國境內直接或間接派發，而此項申請亦並非在美國出售股份的要約。發售股份並無亦將不會根據美國證券法或美國任何州證券法登記，且不得在美國境內提呈發售、出售、抵押或轉讓。惟根據美國證券法及適用美國州證券法獲豁免登記規定或並非受該等登記規定規限的交易除外。發售股份只可依據美國證券法S規例以及進行發售及出售的司法權區適用法例在美國境外以離岸交易方式提呈發售及出售。將不會於美國進行發售股份的公開發售。

在任何根據有關司法權區法例不得發送、派發或複製本申請表格及招股章程之司法權區內，概不得以任何方式發送或派發或複製（全部或部分）本申請表格及招股章程。本申請表格及招股章程僅致予閣下本人。概不得發送或派發或複製本申請表格或招股章程的全部或部分。如未能遵守此項指令，可能違反美國證券法或其他司法權區的適用法例。

致：福森藥業有限公司
獨家保薦人
聯席全球協調人
聯席賬簿管理人
聯席牽頭經辦人
香港包銷商

1 We confirm that we have (i) complied with the Guidelines for Electronic Public Offerings and the Operational Procedures for White Form eIPO Applications submitted via banks/stockbrokers and all applicable laws and regulations (whether statutory or otherwise) in relation to the provision of our White Form eIPO services in connection with the Hong Kong Public Offering; and (ii) read the terms and conditions and application procedures set out in the Prospectus and this Application Form and agree to be bound by them. Applying on behalf of each of the underlying applicants to whom this application relates, we:

- apply for the number of Hong Kong Offer Shares set out below, on the terms and conditions of the Prospectus and this Application Form, and subject to the Memorandum of Association and the Articles of Association;
- enclose payment in full for the Hong Kong Offer Shares applied for, including 1% brokerage, 0.0027% SFC transaction levy and 0.005% Stock Exchange trading fee;
- confirm that the underlying applicants have undertaken and agreed to accept the Hong Kong Offer Shares applied for, or any lesser number allocated to such underlying applicants on this application;
- undertake and confirm that the underlying applicant(s) and the person for whose benefit the underlying applicant(s) is/are applying; or has/have not applied for or taken up, or indicated an interest for, or received or been placed or allocated (including conditionally and/or provisionally), and will not apply for or take up, or indicate an interest for, any Offer Shares under the International Offering nor participate in the International Offering;
- understand that these declarations and representations will be relied upon by the Company and the Joint Global Coordinators in deciding whether or not to make any allotment of Hong Kong Offer Shares in response to this application, and that the underlying applicants may be prosecuted if they made a false declaration;
- authorise the Company to place the name(s) of the underlying applicant(s) on the register of members of the Company as the holder(s) of any Hong Kong Offer Shares to be allotted to them, and our Company and/or its agent (subject to the terms and conditions set out in this Application Form) to send any share certificate(s) and/or any refund cheque and/or e-Refund payment instruction(s) (where applicable) to the that underlying applicant in accordance with the procedures prescribed in this Application Form and in the Prospectus except where the underlying applicant has applied for 1,000,000 or more Hong Kong Offer Shares and that underlying applicant has collected any Share certificate(s) in person in accordance with the procedures prescribed in this Application and in the Prospectus;
- request that any e-Refund payment instructions be dispatched to the application payment account where the underlying applicants had paid the application monies from a single bank account;
- request that any refund cheque(s) be made payable to the underlying applicant(s) who had used multiple bank accounts to pay the application monies and to send any such refund cheque(s) by ordinary post at that underlying applicant's own risk to the address stated on the application in accordance with the procedures prescribed in this Application Form and in the Prospectus;
- confirm that each underlying applicant has read the terms and conditions and application procedures set out in this Application Form and in the Prospectus and agrees to be bound by them;
- represent, warrant and undertake that the allotment of or application for the Hong Kong Offer Shares to the underlying applicant or by underlying applicant or for whose benefit this application is made would not require the Company to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong;
- agree that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong; and
- agree that the Company, the Joint Global Coordinators, the Sole Sponsor, the Joint Bookrunners, the Joint Lead Managers, the Underwriters and their respective directors, advisors, agents and any other parties involved in the Global Offering are entitled to rely on any warranty, representation and declaration made by us or the underlying applicants.

我們確認已(i)遵照電子公開發售指引及透過銀行/股票經紀遞交白表eIPO申請的運作程序以及我們就香港公開發售提供白表eIPO服務的所有適用法例及規例(無論法定與否);及(ii)閱讀招股章程及本申請表格所載的條款和條件及申請程序，並同意受其約束。為代表與本申請有關的相關申請人作出申請，我們：

- 按招股章程及本申請表格所載條款及條件，並在遵守組織章程大綱及組織章程細則的情況下，申請認購以下數目的香港發售股份；
- 隨附申請認購香港發售股份所需的全數款項(包括1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費)；
- 確認相關申請人已承諾及同意接納彼等根據本申請所申請認購的香港發售股份，或任何較少數目的香港發售股份；
- 承諾及確認相關申請人及相關申請人為其利益而提出申請的人士並無申請認購或已申請認購或承諾或表示有意認購或收取或獲配售或分配(包括有條件及/或暫定)，亦將不會申請認購或承諾或表示有意認購國際發售的任何發售股份，亦無參與國際發售；
- 明白本公司與聯席全球協調人將依賴此等聲明及陳述，以決定是否就本申請配發任何香港發售股份，及相關申請人如作出虛假聲明，可能會遭受檢控；
- 授權本公司將相關申請人的姓名/名稱列入本公司股東名冊內，作為配發予彼等的任何香港發售股份的持有人，而本公司及/或其代理(在符合本申請表格所載條款及條件的規限下)根據本申請表格及招股章程所載程序向相關申請人任何寄發股票及/或任何退款支票及/或電子退款指示(如適用)，除非相關申請人申請認購1,000,000股或以上香港發售股份，並按本申請表格及招股章程所載程序親身領取任何股票；
- 要求把任何電子退款指示發送到相關申請人以單一銀行賬戶繳付申請股款的付款賬戶；
- 要求任何以多個銀行賬戶繳付申請股款的相關申請人的退款支票以相關申請人為抬頭人，並根據本申請表格及招股章程所述程序將任何有關退款支票以普通郵遞方式寄發到申請所列的地址，郵誤風險概由相關申請人自行承擔；
- 確認各相關申請人已細閱本申請表格及招股章程所載條款及條件以及申請程序，並同意受其約束；
- 聲明、保證及承諾向相關申請人或由相關申請人或為其利益而提出本申請的人士配發或由該等人士申請香港發售股份，不會引致本公司須遵從香港以外任何地區的法例或規例的任何規定(不論是否具法律效力)；
- 同意本申請、申請獲接納及因而產生的合約，均受香港法例管轄，並按其詮釋；及
- 同意本公司、聯席全球協調人、獨家保薦人、聯席賬簿管理人、聯席牽頭經辦人、包銷商、彼等各自的董事、顧問、代理及參與全球發售的任何其他人士有權依賴於吾等或相關申請人作出的任何保證、聲明或陳述。

Signature 簽名

Date 日期

Name of signatory 簽署人姓名/名稱

Capacity 身份

2 We, on behalf of the underlying applicants, offer to purchase 我們(代表相關申請人)提出認購

Total number of Hong Kong Offer Shares 香港發售股份總數

Hong Kong Offer Shares on behalf of the underlying applicants whose details are contained in the read-only CD-ROM submitted with this Application Form.
代表相關申請人提出認購的香港發售股份(申請人的詳細資料載於連同本申請表格遞交的唯讀光碟內)。

3 A total of 隨附合共

Cheque(s) 支票

Cheque number(s) 支票編號

are enclosed for a total sum of 其總金額為

HKS 港元

Name of Bank 銀行名稱

4 Please use BLOCK letters 請用正楷填寫

Name of White Form eIPO Service Provider 白表eIPO服務供應商名稱

Chinese Name 中文名稱

Name of contact person 聯絡人姓名

Address 地址

White Form eIPO Service Provider ID 白表eIPO服務供應商編號

Contact number 聯絡電話號碼

Fax number 傳真號碼

For Broker use 此欄供經紀填寫
Lodged by 申請由以下經紀遞交

Broker No. 經紀號碼

Broker's Chop 經紀印章

For Bank Use 此欄供銀行填寫

GUIDE TO COMPLETING THIS APPLICATION FORM

References to boxes below are to the numbered boxes on the Application Form.

1 Sign and date the Application Form in Box 1. Only a written signature will be accepted.

The name and the representative capacity of the signatory should also be stated.

To apply for Hong Kong Offer Shares using this Application Form, you must be named in the list of **White Form eIPO Service Providers** who may provide **White Form eIPO services** in relation to the Hong Kong Public Offering, which was released by the SFC.

2 Put in Box 2 (in figures) the total number of Hong Kong Offer Shares for which you wish to apply on behalf of the underlying applicants.

Applicant details of the underlying applicants on whose behalf you are applying must be contained in one data file in read-only CD-ROM format submitted together with this Application Form.

3 Complete your payment details in Box 3.

You must state in this box the number of cheque(s) you are enclosing together with this Application Form; and you must state on the reverse of each of those cheque(s) (i) your **White Form eIPO Service Provider ID** and (ii) the file number of the data file containing application details of the underlying applicant(s).

The dollar amount(s) stated in this box must be equal to the amount payable for the total number of Hong Kong Offer Shares applied for in Box 2.

All cheque(s) and this Application Form together with a sealed envelope containing the CD-ROM, if any, must be placed in the envelope bearing your company chop.

For payments by cheque, the cheque must:

- be in Hong Kong dollars;
- be drawn on a Hong Kong dollar bank account in Hong Kong;
- show your (or your nominee's) account name;
- be made payable to "**Wing Lung Bank (Nominees) Limited — Fusen Pharmaceutical Public Offer**";
- be crossed "Account Payee Only";
- not be post-dated; and
- be signed by the authorised signatories of the **White Form eIPO Service Provider**.

Your application may be rejected if any of these requirements is not met or if the cheque is dishonoured on its first presentation.

It is your responsibility to ensure that details on the cheque(s) submitted correspond with the application details contained in the CD-ROM or data file submitted in respect of this application. The Company and the Joint Global Coordinators have full discretion to reject any applications in the case of discrepancies.

No receipt will be issued for sums paid on application.

4 Insert your details in Box 4 (using BLOCK letters).

You should write your name, **White Form eIPO Service Provider ID** and address in this box. You should also include the name and telephone number of the contact person at your place of business and where applicable, the Broker No. and Broker's Chop.

Personal Data

Personal Information Collection Statement

This Personal Information Collection Statement informs the applicant for, and holder of, Hong Kong Offer Shares, of the policies and practices of the Company and the Hong Kong Share Registrar in relation to personal data and the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong) (the "Ordinance").

1. Reasons for the collection of your personal data

It is necessary for applicants and registered holders of securities to supply their latest correct personal data to the Company or its agents and/or the Hong Kong Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the Hong Kong Share Registrar.

Failure to supply the requested data may result in your application for securities being rejected, or in delay or the inability of the Company or the Hong Kong Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfers of the Hong Kong Offer Shares which you have successfully applied for and/or the dispatch of share certificate(s) and/or e-Refund payment instructions and/or refund cheque(s) to which you are entitled.

It is important that securities holders inform the Company and the Hong Kong Share Registrar immediately of any inaccuracies in the personal data supplied.

2. Purposes

The personal data of the securities holders may be used, held, processed and/or stored by whatever means for the following purposes:

- processing your application and e-Refund payment instructions and refund cheque, where applicable, verification of compliance with the terms and application procedures set out in this Application Form and the Prospectus and announcing results of allocation of the Hong Kong Offer Shares;
- compliance with all applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of securities holders including, where applicable, HKSCC Nominees;
- maintaining or updating the registers of securities holders of the Company;
- conducting or assisting to conduct signature verifications, any other verifications or exchange of information;
- establishing benefit entitlements of securities holders of the Company, such as dividends, rights issues and bonus issues, etc;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and securities holder profiles;
- making disclosures as required by laws, rules or regulations;
- disclosing identities of successful applicants by way of pressing announcement(s) or otherwise;
- disclosing relevant information to facilitate claims on entitlements; and
- any other incidental or associated purposes relating to the above and/or to enable the Company and the Hong Kong Share Registrar to discharge their obligations to securities holders and/or regulators and/or any other purposes to which the securities holders may from time to time agree.

3. Transfer of personal data

Personal data held by the Company and the Hong Kong Share Registrar relating to the securities holders will be kept confidential but the Company and the Hong Kong Share Registrar may, to the extent necessary for achieving any of the above purposes, disclose, obtain, transfer (whether within or outside Hong Kong) the personal data of the applicants and the holders of securities to, from or with any and all of the following persons and entities:

- the Company's appointed agents such as financial advisers, receiving bank and overseas principal share registrar;
- where applicants for securities request a deposit into CCASS, HKSCC or HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company or the Hong Kong Share Registrar in connection with the operation of their respective business;
- the Stock Exchange, the SFC and any other statutory regulatory or governmental bodies or otherwise as required by laws, rules or regulations; and
- any persons or institutions with which the securities holders have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers, etc.

4. Retention of personal data

The Company and the Hong Kong Share Registrar will keep the personal data of the applicants and holders of securities for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Ordinance.

5. Access to and correction of personal data

The Ordinance provides the Securities holders have the right to ascertain whether the Company or the Hong Kong Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. In accordance with the Ordinance, the Company and the Hong Kong Share Registrar have the right to charge a reasonable fee for the processing of any data access requests.

All requests for access to data or correction of data should be addressed to us, at our registered address disclosed in the "Corporate Information" section of the Prospectus or as notified from time to time, for the attention of the joint company secretaries, or to the Hong Kong Share Registrar for the attention of the privacy compliance officer for the purposes of the Ordinance.

By signing an Application Form, you agree to all of the above.

DELIVERY OF THIS APPLICATION FORM

This completed Application Form, together with the appropriate cheque(s) must be submitted to the following receiving banks by 4:00 p.m. on Wednesday, July 4, 2018 together with a sealed envelope containing the CD-ROM:

Wing Lung Bank Limited

Room 1503, Wing Lung Bank Centre
636 Nathan Road
Kowloon

填寫本申請表格的指引

下列號碼指申請表格中各欄的編號。

1 在申請表格欄**1**簽署及填上日期。只接受親筆簽名。

簽署人的姓名／名稱及代表身份亦必須註明。

使用本申請表格申請認購香港發售股份，閣下必須為名列於證監會公佈的白表eIPO服務供應商名單內可以就香港公開發售提供白表eIPO服務的人士。

2 在欄**2**填上閣下欲代表相關申請人申請認購的香港發售股份總數(以數字填寫)。

閣下代表相關申請人作出申請的申請人資料必須放置於一個連同本申請表格遞交的唯讀光碟格式的資料檔案內。

3 在欄**3**填上閣下的付款詳情。

閣下必須在本欄註明閣下連同本申請表格隨附的支票數目；及閣下必須在每張支票的背面註明(i)閣下的白表eIPO服務供應商編號及(ii)載有相關申請人申請詳細資料的資料檔案的檔案編號。

本欄所註明的金額必須與欄**2**所申請認購的香港發售股份總數對應金額相同。

所有支票及本申請表格，連同裝有該光碟的密封信封(如有)必須放進加蓋閣下公司印章的信封內。

倘以支票付款，該支票必須：

- 為港元支票；
- 由在香港的港元銀行賬戶開出；
- 顯示閣下(或閣下的代名人)的賬戶名稱；
- 註明抬頭人為「永隆銀行受託代管有限公司 — 福森藥業公開發售」；
- 劃線註明「只准入抬頭人賬戶」；
- 不得為期票；及
- 由白表eIPO服務供應商的授權簽署人簽署。

倘支票不符合上述任何規定；或支票首次過戶不獲兌現，則閣下的申請可遭拒絕受理。

閣下須確保所遞交的支票的詳細資料，與就本申請遞交的光碟或資料檔案所載的申請詳細資料相同。倘有差異，本公司及聯席全球協調人有絕對酌情權拒絕接受任何申請。

申請所繳付的金額不會獲發收據。

4 在欄**4**填上閣下的詳細資料(用正楷)。

閣下必須在本欄填上閣下的名稱、白表eIPO服務供應商編號及地址。閣下亦必須填寫閣下辦公地點的聯絡人士的姓名及電話號碼及(如適用)經紀號碼及蓋上經紀印章。

個人資料

個人資料收集聲明

此項個人資料收集聲明是向香港發售股份的申請人和持有人說明有關本公司及香港證券登記處有關個人資料和香港法例第486章《個人資料(私隱)條例》(「條例」)方面的政策和慣例。

1. 收集閣下個人資料的原因

證券申請人及登記持有人以本身名義申請認購證券或轉讓或受讓證券時或尋求香港證券登記處的服務時，必須向本公司或其代理及/或香港證券登記處提供其最新的準確個人資料。

未能提供所要求的資料可能導致閣下申請認購證券被拒或延遲，或本公司或香港證券登記處無法落實轉讓或提供服務。此舉也可能妨礙或延遲登記或轉讓閣下成功申請認購的香港發售股份及/或寄發閣下應得的股票及/或電子退款指示及/或退款支票。

證券持有人所提供的個人資料如有任何錯誤，須立即通知本公司及香港證券登記處。

2. 目的

證券持有人的個人資料可作以下目的以任何方法使用、持有、處理及/或存置：

- 處理閣下的申請及電子退款指示及退款支票(如適用)、核實是否符合本申請表格及招股章程載列的條款和申請程序以及公佈香港發售股份的分配結果；
- 遵守香港及其他地區的所有適用法例及法規；
- 以證券持有人(包括香港結算代理人(如適用))的名義登記新發行證券或轉讓或受讓證券；
- 存置或更新本公司證券持有人的名冊；
- 進行或協助進行簽名核對、任何其他核對或交換資料；
- 確定本公司證券持有人的受益權利，例如股息、供股和紅股發行等；
- 分發本公司及其附屬公司的通訊；
- 編製統計數據及證券持有人資料；
- 遵照法例、規則或規例的要求作出披露；
- 透過報章公佈或其他方式披露成功申請人士的身份；
- 披露有關資料以便就權益索償；及
- 與上述有關的任何其他附帶或相關目的及/或使本公司及香港證券登記處能履行對證券持有人及/或監管機構承擔的責任及/或證券持有人不時同意的任何其他目的。

3. 轉交個人資料

本公司及香港證券登記處所持有關證券持有人的個人資料將會保密，但本公司及香港證券登記處可以在為達到上述任何目的之必要情況下，向下列任何及所有人士及實體披露、索取或轉交證券申請人及持有人的個人資料(無論在香港境內或境外)：

- 本公司委任的代理，例如財務顧問、收款銀行及主要海外證券登記處；
- 如證券申請人要求將證券存於中央結算系統、香港結算或香港結算代理人；彼等將會就中央結算系統的運作使用有關個人資料；
- 向本公司或香港證券登記處提供與其各自業務營運有關的行政、電訊、電腦、付款或其他服務的任何代理、承包商或第三方服務供應商；
- 聯交所、證監會及任何其他法定監管機關或政府部門或其他法例、規則或法規所要求的機構；及
- 證券持有人與其進行或擬進行交易的任何人士或機構，例如彼等的銀行、律師、會計師或股票經紀等。

4. 個人資料的保留

本公司及其香港證券登記處將按收集個人資料所需的用途保留證券申請人及持有人的個人資料。無需保留的個人資料將會根據條例銷毀或處理。

5. 查閱和更正個人資料

條例賦予證券持有人有權確定本公司或香港證券登記處是否持有其個人資料，並有權索取有關該資料的副本並更正任何不準確資料。根據條例規定，本公司及香港證券登記處有權就處理任何查閱資料的要求收取合理費用。

根據條例，所有查閱資料或更正資料的要求應按招股章程「公司資料」一節所披露或不時通知的本公司註冊地址送交聯席公司秘書，或向香港證券登記處的個人資料私隱事務主任提出。

閣下簽署申請表格，即表示同意上述各項。

遞交本申請表格

填妥的申請表格，連同有關支票以及載有相關光碟的密封信封，必須於2018年7月4日(星期三)下午四時正之前，送達下列收款銀行：

永隆銀行有限公司

九龍
彌敦道636號
永隆銀行中心1503室